Thursday, April 09, 2015 3:55:26 PM
Here is the part I like!>>
JK: I feel like I've already seen proof of concept in Mesoblast's product, Athersys' product and NeoStem's product, NBS10 (autologous, bone marrow-derived, CD34+ /CXCR4+ enriched cells). By default, I expect the Pluristem product, PLX-PAD (full-term placenta-derived adherent stromal cells), to work. PLX-PAD is a heterogeneous mixture of cells, which differs from Mesoblast's mesenchymal precursor cells and Athersys' MultiStem, which are both homogeneous groups of cells. The company's lead indications are peripheral artery disease and muscle injury, including that associated with surgery for total hip replacement.
TLSR: You've mentioned NeoStem a couple of times. Last November the company reported top-line results in its Phase 2b PreSERVE-AMI trial of NBS10 in ST segment elevation myocardial infarction (STEMI). It did not meet its primary endpoint of cardiac perfusion. Yet you see proof of concept. What do you mean?
JK: The STEMI trial showed a tremendous mortality benefit and an improvement in virtually every secondary measure. That improvement, by the way, was recently affirmed at the American College of Cardiology, when Dr. Arshed Quyyumi, the principal investigator, presented the 12-month follow-up data. What I see in the NeoStem PreSERVE-AMI trial is a very successful study. The bears will say one of its primary endpoints, perfusion, didn't show a sufficiently low p-value. But perfusion is not an approvable endpoint in a pivotal trial anyway. Mortality is, and NeoStem has shown a mortality benefit.
If a stock is cut in half on bad Phase 2 data, whether NeoStem or Athersys, I would absolutely be buying more, because I don't believe the Phase 2 endpoints are significant in either trial. The Phase 2 data that NeoStem reported were good data. What investors have to understand is that sometimes Phase 2 data won't give a low enough p-value, but does give information on what a company needs to be successful in Phase 3. If, on the other hand, the Athersys or NeoStem data show no trends, and no difference whatsoever between placebo and the active arm, that would be very disappointing and would suggest something is not right
Recent LSTA News
- Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial • GlobeNewswire Inc. • 09/17/2024 12:00:00 PM
- Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy • GlobeNewswire Inc. • 07/18/2024 12:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/28/2024 12:30:00 PM
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer • GlobeNewswire Inc. • 05/20/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:16 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:47 PM
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM